SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Anti-inflammatoryResearch peptide

KPV

aka Lys-Pro-Val

C-terminal tripeptide of alpha-MSH with anti-inflammatory effects in gut and skin.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

KPV is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone), retaining anti-inflammatory activity without pigmentation or appetite effects.

Source
  • Synthesized in research laboratories
Forms
  • Oral capsule
  • Subcutaneous injection
  • Topical

Mechanism of action

Enters cells directly and interferes with NF-kB and inflammatory cytokine signaling; also displays antimicrobial activity at high local concentration.

Pathways
  • · NF-kB suppression
  • · TNF-alpha and IL-6 modulation
  • · Direct antimicrobial action

How it acts on the body

Alpha-MSH has well-documented anti-inflammatory effects but also drives pigmentation and appetite via the MC1/MC4 receptors. KPV preserves the anti-inflammatory tail of the molecule while shedding the receptor-binding portion, which is why it produces calming effects in inflamed tissue without changing skin color or hunger.

Its small size lets it enter cells directly and act on NF-kB and downstream cytokine production. It is particularly studied in inflammatory bowel disease models and in skin/wound contexts where topical or oral delivery is practical.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

TNF-alphaDecreases
Suppressed via NF-kB pathway interference.
IL-6Decreases
Downstream inflammatory signaling reduced.
Alpha-MSH pigmentation signalStabilizes
No MC1/MC4 activation, so no pigmentation or appetite effect.

Effects on the body

Decreases
Local inflammation
Supports
Mucosal and skin healing
Inhibits
Bacterial growth at high local concentration

Organ system effects

Digestive / Gut

Anti-inflammatory in IBD models.

Skin

Reduces local inflammation in wound and dermatitis contexts.

Immune System

Calms NF-kB-driven cytokine signaling.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Anti-inflammatory without immunosuppression
  • No pigmentation or appetite effect

Potential side effects

Common
  • · Mild injection-site reaction
Rare
  • · Headache
Serious
  • · Limited long-term human data

Drug interactions

No notable interactions reported.

Pairing context

Often combined with
  • BPC-157
    Complementary mucosal and tissue-repair effects.
Avoid combining with
  • Severe immunosuppression
    Anti-inflammatory layering may compound vulnerability.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.